Peripheral Neuropathy
Damage to the peripheral nerves — usually with a findable cause, and not the same as a brain or spinal-cord disease
What it is
Peripheral neuropathy is damage to the peripheral nerves — the nerves running out to the limbs, skin and organs, distinct from the brain and spinal cord of the central nervous system. That distinction matters, because the symptoms — numbness, tingling, burning, pins and needles, weakness — overlap with central conditions like multiple sclerosis and with anxiety, and telling them apart is much of the clinical work. The commonest form is a distal symmetric polyneuropathy: it begins in the longest nerves first, so it starts in the feet and moves upward, symmetrically, in the classic 'glove and stocking' pattern — toes before fingers, both sides at once. That pattern is itself a clue to the mechanism, and it is different from a single trapped nerve (like carpal tunnel) or a single nerve root (like cervical radiculopathy), which affect one specific territory rather than everything distal. The single most important thing about peripheral neuropathy is that it usually has a findable, sometimes treatable cause — diabetes above all, then vitamin B12 deficiency, alcohol, certain drugs, thyroid disease, kidney disease, and a range of less common conditions — which is why the diagnosis is not the end of the assessment but the start of a search for why.
Why it matters
Two things make this worth a page. The first is that it is a mimic and is mimicked: the sensory symptoms overlap with multiple sclerosis, and a great deal of anxious self-diagnosis runs in both directions — people with benign, transient tingling fearing MS, and people with a genuine treatable neuropathy attributing it to stress. Naming the pattern (distal, symmetric, ascending, sensory-first) is how the common peripheral cause is separated from the central one, which presents differently. The second is that the search for a cause is the point. Diabetes and prediabetes are the leading cause worldwide, and glucose control genuinely affects the course; B12 deficiency is common, easily missed, and reversible if caught before the damage becomes permanent; alcohol, some chemotherapy and other drugs, and thyroid and kidney disease are all identifiable. So the honest framing is optimistic in a specific way: the symptoms are often manageable and the underlying cause is often findable and sometimes correctable — but the pain of established neuropathy is only modestly helped by medication, which is the part that tends to be oversold, and there is no drug that reliably regrows damaged nerves.
What BioSignal knows about treating this
What works for Peripheral Neuropathy
BioSignal’s clinical summary, most important first.
- Finding and treating the cause — the central task; glucose control for diabetic neuropathy, B12 replacement for deficiency, reducing alcohol, reviewing culprit drugs
- Glycaemic control — affects the course of diabetic neuropathy, though it does not reverse established damage
- Neuropathic pain medication — gabapentinoids, SNRIs (duloxetine), sodium-channel blockers, and tricyclics; effect sizes are modest and broadly comparable
- Topical agents (e.g. capsaicin) in selected cases
- Avoiding opioids for chronic neuropathic pain — not recommended, given poor long-term benefit and real harm
- Foot care and injury prevention — critical where sensation is lost, because unnoticed injuries lead to ulcers
- Physiotherapy and balance work where weakness or unsteadiness is present
Signal Records relevant to this condition
Interventions and contributing factors — some of these records describe a cause rather than a cure. The rating shown is BioSignal’s confidence in that Signal Record, not a claim about how well it treats this condition. Open any of them for the full evidence.
New to this? Read these first
How this usually unfolds
- Recognize risk factors
- Get diagnosed
- Track key biomarkers
- Lifestyle first
- Evidence-based treatment
- Long-term monitoring
Who is at risk
- Diabetes and prediabetes — the leading cause worldwide, and the reason blood glucose is the first test
- Vitamin B12 deficiency — common, easily missed, and reversible if treated early
- Alcohol excess
- Certain medications — notably some chemotherapy agents, and others
- Chronic kidney disease and thyroid disease
- Inherited neuropathies (e.g. Charcot-Marie-Tooth) and immune-mediated neuropathies
- HIV and some other infections; and a proportion remain idiopathic despite thorough evaluation
How it's diagnosed
The diagnosis is clinical — the pattern and the examination — and the investigation is aimed less at proving neuropathy than at finding its cause. The history and examination establish the pattern: distal, symmetric, sensory-predominant, ascending from the feet suggests the common polyneuropathy, while asymmetric, patchy, or single-territory symptoms point elsewhere (a trapped nerve, a root, or a different process). The evidence-based first-line laboratory tests are specific and high-yield: blood glucose (for diabetes and impaired glucose tolerance), serum vitamin B12 with its metabolites (methylmalonic acid, because B12 at the low-normal range can still be deficient at the tissue level), and serum protein electrophoresis. Thyroid and kidney function are commonly added. Nerve conduction studies and EMG are useful when the diagnosis is unclear, when the pattern is atypical, or when an inflammatory or inherited cause is suspected — not as a routine confirmation of an obvious distal sensory neuropathy. The most important diagnostic discipline is the one that separates this from its central mimic: peripheral neuropathy follows nerve territories and is length-dependent, whereas multiple sclerosis produces central patterns and other signs — and a small number of neuropathies (inflammatory, rapidly progressive) need urgent rather than routine assessment.
Key biomarkers
Lifestyle
Explore this condition across BioSignal
Related Foundations
Related Signal Records
Related body systems
Frequently asked questions
Is tingling or numbness in my feet a sign of MS?
Usually not — and the pattern is what tells them apart, so it is worth understanding rather than worrying. Peripheral neuropathy, the common cause of numb or tingling feet, is a problem of the peripheral nerves, and it has a signature: it is length-dependent, so it starts in the longest nerves — the feet — and moves upward symmetrically, both sides together, in a 'glove and stocking' distribution, and it is usually sensory first (numbness, tingling, burning) before any weakness. Multiple sclerosis is a disease of the central nervous system and behaves differently: its episodes tend to be more sudden, more likely to be one-sided or to involve a discrete area, and to come with other central signs — an eye going painful and blurred, double vision, a band of numbness across the trunk, problems with coordination or balance that are central rather than length-dependent. Symmetric, ascending, feet-first numbness is the peripheral pattern, and its commonest causes are diabetes and B12 deficiency, not MS. That said, neither self-diagnosis nor self-reassurance is the right endpoint: persistent numbness deserves assessment, because the useful thing a clinician does here is not just excluding MS but finding the cause of the neuropathy, which is often treatable. If your symptoms are one-sided, came on suddenly, or come with visual or balance problems, that is a different pattern and a reason to be seen sooner.
What causes peripheral neuropathy?
Usually something findable, which is the most important and most hopeful fact about it. Diabetes and prediabetes are the leading cause worldwide — high blood sugar damages the small nerves over time — and they are the reason blood glucose is the first test anyone with a distal neuropathy should have. After that, the high-yield causes are vitamin B12 deficiency (common, often missed, and reversible if caught early), alcohol excess, certain medications including some chemotherapy drugs, and thyroid and kidney disease. Less common causes include inherited neuropathies, immune-mediated neuropathies, and some infections. Evidence-based evaluation reflects this: the three first-line laboratory tests with the highest yield are blood glucose, serum B12 with its metabolites, and serum protein electrophoresis, usually with thyroid and kidney function alongside. A proportion of neuropathies remain 'idiopathic' — no cause found despite a thorough search — and that is a real and frustrating category, but it is a diagnosis reached after looking, not instead of looking. The reason the search matters is that several of these causes are treatable, and treating them early can stop the damage progressing and sometimes reverse it, which is not true once the nerve damage is established.
Can it be reversed, or will it get worse?
It depends entirely on the cause and on how early it is caught, and BioSignal will be honest about both the hope and its limits. When there is a treatable cause found early, the picture can be genuinely good: B12 deficiency treated before the damage becomes fixed can improve; alcohol-related neuropathy can stabilise or improve with abstinence; drug-induced neuropathy may recede when the drug is changed. For diabetic neuropathy, good glucose control affects the course and slows progression, which is a real and worthwhile effect. But there are two hard truths alongside this. Once nerve damage is established, it is often permanent — the treatable window is earlier rather than later, which is the argument for taking early symptoms seriously rather than waiting. And there is no medication or supplement that reliably regrows damaged peripheral nerve; the products sold on that promise are selling something the evidence does not support. So the honest summary is: the underlying cause is often treatable and worth pursuing hard and early; the symptoms of established neuropathy are managed rather than cured; and progression can frequently be slowed even when reversal is not possible.
What actually helps the pain?
Medication helps, modestly and about equally across the options, and it is worth having realistic expectations before starting. The American Academy of Neurology's guideline compared the drug classes for painful diabetic neuropathy and found gabapentinoids (like gabapentin and pregabalin), SNRIs (like duloxetine), sodium-channel blockers, and tricyclic antidepressants all have comparable effect sizes — modest ones, standardised mean differences in the region of 0.4 to 0.6. That comparability is useful information: there is no single clearly superior drug, so the choice is guided by your other conditions, side effects, and what you tolerate, rather than by one being dramatically better. The guideline is also explicit that opioids should NOT be used for painful diabetic neuropathy — the long-term benefit is poor and the harms are real, which is worth knowing if they are offered. Topical treatments such as capsaicin help some people. What none of these do is remove the pain entirely or fix the nerve; the realistic goal is a meaningful reduction that makes daily life and sleep better, and it is reasonable to try a different agent if the first does not help, because response varies between people. Treating the underlying cause remains the part that changes the disease rather than just masking it.
I have diabetes — how do I protect my feet?
By looking, because you may not be able to feel — and this is one of the most consequential pieces of practical advice on the page. When neuropathy reduces sensation in the feet, the protective alarm system that normally makes you notice a blister, a stone in your shoe, or a small cut stops working, and injuries that would ordinarily be trivial go unnoticed, get worse, and can become ulcers that are slow to heal and occasionally lead to serious complications. The countermeasure is to replace feeling with looking: check your feet daily, including the soles and between the toes, for cuts, blisters, redness or changes; feel inside your shoes before putting them on; avoid walking barefoot; keep the skin cared for; and have any wound that is not healing looked at promptly rather than waited out. Well-fitting footwear matters, and regular professional foot review is part of good diabetes care for a reason. This is not excessive caution: foot problems in diabetic neuropathy are common, preventable, and serious when missed, and the daily habit of looking is genuinely protective. Alongside it, glucose control slows the neuropathy itself, so the two work together.
When should nerve symptoms be checked urgently?
When they are fast, spreading, or come with weakness — because while most peripheral neuropathy develops slowly and is assessed in an ordinary appointment, a few patterns need urgent attention. Seek urgent care for numbness or weakness that is developing rapidly over hours to days, especially if it is ascending up the legs, or if it comes with difficulty breathing or swallowing — a rapidly progressive weakness can indicate an inflammatory neuropathy (such as Guillain-Barré syndrome) that is a medical emergency. Seek prompt assessment for new weakness rather than just sensory symptoms, for symptoms that are markedly asymmetric or affecting one area severely, for loss of bladder or bowel control, or for neuropathy alongside a systemic illness. Sudden one-sided symptoms, or symptoms with facial droop, slurred speech, or visual loss, point toward the brain rather than the peripheral nerves and should be treated as a possible stroke. For the common picture — a gradual, symmetric, feet-first numbness or tingling over weeks to months — the issue is not usually urgency but making sure the cause is found, which means seeing a doctor for the right tests rather than either panicking or ignoring it.
Evidence summary
Peripheral neuropathy is damage to the peripheral nervous system, most commonly a length-dependent distal symmetric polyneuropathy producing feet-first, symmetric, ascending, sensory-predominant symptoms ('glove and stocking') — a pattern that distinguishes it from single mononeuropathies, radiculopathies, and the central patterns of multiple sclerosis. Diabetes and prediabetes are the leading cause worldwide; other common and often treatable causes include vitamin B12 deficiency, alcohol, medications (notably some chemotherapies), and thyroid and kidney disease, with inherited, inflammatory, infectious and idiopathic categories also recognised. Evidence-based first-line evaluation (AAN practice parameter) identifies the three highest-yield laboratory tests as blood glucose, serum B12 with metabolites (methylmalonic acid, since low-normal B12 may be deficient at tissue level), and serum protein electrophoresis; nerve conduction studies and EMG are reserved for atypical patterns, suspected inflammatory or inherited causes, or diagnostic uncertainty rather than routine confirmation. Management centres on identifying and treating the cause: glycaemic control affects the course of diabetic neuropathy without reversing established damage, B12 replacement can help if given before damage is fixed, and culprit drugs and alcohol are modifiable. For neuropathic pain, the AAN 2022 guideline found gabapentinoids (SMD 0.44), SNRIs (0.47), sodium-channel blockers (0.56) and SNRI/opioid dual-mechanism agents (0.62) have comparable, modest effect sizes with no single superior class, and explicitly recommends against opioids for painful diabetic neuropathy; tricyclics and topical capsaicin are additional options. No agent reliably regenerates damaged peripheral nerve. Foot care is critical where sensation is lost, given the risk of unnoticed injury progressing to ulceration. Rapidly progressive, ascending, or markedly asymmetric weakness (e.g. Guillain-Barré syndrome) requires urgent assessment. This page covers peripheral neuropathy; multiple sclerosis, cervical radiculopathy, type 2 diabetes, B12 status and hypothyroidism are separate objects, and sudden one-sided or central symptoms are guarded as possible stroke.
References & sources
- Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary — report of the AAN Guideline Subcommittee. Neurology 2022;98(1):31-43 (PMID 34965987; DOI 10.1212/WNL.0000000000013038)
- Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017;40(1):136-154 (PMID 27999003; DOI 10.2337/dc16-2042)
- England JD, Gronseth GS, Franklin G, et al. Practice parameter: evaluation of distal symmetric polyneuropathy — role of laboratory and genetic testing (an evidence-based review). Neurology 2009;72(2):185-192 (PMID 19056666; DOI 10.1212/01.wnl.0000336370.51010.a1)
Educational information — not medical advice
Is this condition page clear, accurate, and useful? Your feedback shapes what we review next.
Give feedback